Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,774.50
Ask: 1,775.50
Change: 0.00 (0.00%)
Spread: 1.00 (0.056%)
Open: 1,775.50
High: 1,778.50
Low: 1,769.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Stocks at one-month high on Vodafone capital return

Fri, 21st Feb 2014 11:45

- Vodafone and RBS provide a lift- Vodafone capital return lifts sentiment- IHG, Glencore Xstrata hit by downgrades- FTSE 100 at highest level in monthtechMARK 2,884.38 +0.29%FTSE 100 6,827.26 +0.21%FTSE 250 16,401.56 +0.20%UK stocks rose to levels not seen in a month on Friday as a windfall for investors at Vodafone and rumoured restructuring plans at RBS gave sentiment a lift.Markets were particularly buoyant this morning as investors speculated about which stocks could benefit from Vodafone shareholders redistributing their cash following the group's $130bn deal to sell its 45% stake in Verizon Wireless.According to analysts at Bank of America Merrill Lynch, the deal, which completes today, will be the largest capital return in corporate history and will have a drastic impact on UK trading volumes over the next few weeks.The FTSE 100 had pared gains by midday but was still trading 0.2% higher at 6,827; it has not closed above this level since January 21st. "London's main index holds above the 6,800 level for now, putting it in a position to challenge the January high of 6,867; providing the positive mood is sustained into the final week of February," said Chris Beauchamp, Market Analyst at IG. He said that the current rally "may have a little further to run".Investors largely shrugged off data this morning showing a worse-than-expected 1.5% fall in UK retail sales volumes in January. Vodafone, RBS and Glaxo provide a liftTelecoms titan Vodafone was making decent gains this morning with shareholders today set to receive a windfall from the company's sale of its holding in its US joint venture with Verizon.RBS was higher amid reports that the bank will announce plans to slash as many as 30,000 jobs, reducing its staff count to the lowest levels in more than 10 years. The speculation comes ahead of the group's 2013 results due out next week, alongside which it is expected to unveil a massive restructuring programme of its divisions.Pharmaceuticals giant GlaxoSmithKline edged higher after European regulators recommended marketing authorisation for umeclidinium, its once-daily treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.Millennium & Copthorne, the hotel firm, jumped after reporting record revenues and profits for 2013 as fourth-quarter results were boosted by the one-off sale of the bulk of the Glyndebourne development in Singapore.Sector peer InterContinental Hotels Group, however, was trading in the red after Credit Suisse lowered its recommendation from 'neutral' to 'underperform', pointing out that the shares are trading within just 4% of their all-time high at a price-to-earnings ratio of 23.Glencore Xstrata was also lower after JPMorgan Cazenove downgraded its rating on the stock from 'overweight' to 'neutral', saying that its peers have overtaken it in terms of capital returns potential.BAE Systems, which disappointed the market with its 2014 guidance yesterday, bounced slightly this morning after Societe Generale raised the stock from 'hold' to 'buy'.FTSE 100 - RisersRoyal Bank of Scotland Group (RBS) 364.10p +2.36%BAE Systems (BA.) 409.00p +2.15%ARM Holdings (ARM) 965.00p +1.90%Vodafone Group (VOD) 233.65p +1.76%Persimmon (PSN) 1,460.00p +1.60%Weir Group (WEIR) 2,355.00p +1.16%Travis Perkins (TPK) 1,984.00p +0.92%Randgold Resources Ltd. (RRS) 4,825.00p +0.81%Severn Trent (SVT) 1,812.00p +0.78%Wolseley (WOS) 3,342.00p +0.75%FTSE 100 - FallersInterContinental Hotels Group (IHG) 1,922.00p -2.68%IMI (IMI) 1,530.00p -2.24%Smiths Group (SMIN) 1,361.00p -2.09%Bunzl (BNZL) 1,469.00p -1.34%easyJet (EZJ) 1,727.00p -1.20%Prudential (PRU) 1,340.00p -1.11%International Consolidated Airlines Group SA (CDI) (IAG) 445.70p -1.07%Meggitt (MGGT) 509.00p -1.07%Glencore Xstrata (GLEN) 336.90p -1.04%ITV (ITV) 205.70p -1.01%FTSE 250 - RisersIP Group (IPO) 231.00p +7.89%Millennium & Copthorne Hotels (MLC) 598.50p +4.72%Essentra (ESNT) 882.00p +4.38%Centamin (DI) (CEY) 52.35p +3.77%Imagination Technologies Group (IMG) 187.90p +2.96%Ocado Group (OCDO) 598.00p +2.48%Big Yellow Group (BYG) 562.00p +2.46%RPC Group (RPC) 630.00p +2.36%Hunting (HTG) 838.00p +2.20%Polymetal International (POLY) 655.00p +2.18%FTSE 250 - FallersVesuvius (VSVS) 458.20p -2.86%Domino's Pizza Group (DOM) 535.00p -2.37%Evraz (EVR) 81.80p -1.56%Rank Group (RNK) 145.00p -1.56%3i Group (III) 400.50p -1.50%PZ Cussons (PZC) 358.80p -1.46%Hellermanntyton Group (HTY) 305.30p -1.45%Synthomer (SYNT) 270.20p -1.39%Cranswick (CWK) 1,288.00p -1.38%Bank of Georgia Holdings (BGEO) 2,375.00p -1.29%BC
More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.